Voyager Therapeutics plans FDA authorization request for its Alzheimer’s gene therapy VY1706 in Q2 2026 after positive preclinical results.
Voyager Therapeutics (NASDAQ:VYGR) reported preclinical data showing its Alzheimer’s gene therapy, VY1706, reduced tau protein in non-human primates by up to 64% with no adverse events. The therapy was well-tolerated at the highest dose tested.
The company expects to seek FDA authorization for clinical testing in Q2 2026, with first-in-human dosing projected for the second half of the year. Voyager also advances its VY7523 anti-tau antibody program, targeting efficacy data in late 2026.
Voyager exited Q1 2026 with $172 million in cash, sufficient to fund operations into 2028. Analysts project over 250% upside for the stock in the next 12 months as drug programs progress.